Circulating Tumor Cell Market Research Report- Forecast to 2030

Circulating Tumor Cell Market Research Report Information By Technology (Research and Drug Development), By Technology (CTC Enrichment, And CTC Detection), By End Users (Hospital & Clinics, Research & Academic Institutes, and Diagnostic Centers), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2030

ID: MRFR/Pharma/0854-CR | 110 Pages | Author: Kinjoll Dey | August 2018         

1 Report Prologue

2 Market Introduction

2.1 Assumptions & Limitations 16

3 Research Methodology

3.1 Research Process 19

3.2 Primary Research 19

3.3 Secondary Research 19

3.4 Market Size Estimation 20

4 Market Dynamics

4.1 Introduction 22

4.2 Drivers 22

4.2.1 Rising Occurrence Of Cancer 22

4.2.2 Increasing Research And Development 22

4.2.3 Rising Geriatric Population 23

4.3 Restraint 23

4.3.1 High Cost Of CTC Tests And Instruments 23

4.4 Opportunity 23

4.4.1 Entering Developing Economies 23

5 Market Factor Analysis

5.1 Value Chain Analysis 25

5.1.1 R&D And Designing 25

5.1.2 Manufacturing 25

5.1.3 Distribution & Sales 26

5.1.4 Post-Sales Review 26

5.2 Porter’s Five Forces Model 26

5.2.1 Bargaining Power Of Suppliers 27

5.2.2 Bargaining Power Of Buyers 27

5.2.3 Threat Of New Entrants 27

5.2.4 Threat Of Substitutes 27

5.2.5 Intensity Of Rivalry 27

6 Circulating Tumor Cell Market, By Application

6.1 Introduction 29

6.2 Clinical 30

6.3 Research 30

6.4 Drug Development 31

7 Circulating Tumor Cell Market, By Technology

7.1 Introduction 33

7.2 CTC Enrichment 34

7.3 CTC Detection 34

7.4 Combined Enrichment And Separation Of CTC (CTC Analysis) 34

8 Circulating Tumor Cell Market, By End-User

8.1 Introduction 36

8.2 Hospital & Clinics 37

8.3 Research & Academic Institutes 37

8.4 Diagnostic Centers 37

9 Global Circulating Tumor Cell Market, By Region

9.1 Introduction 39

9.2 Americas 40

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.2.1 North America 42

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.2.1.1 U.S 44

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.2.1.2 Canada 46

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.2.2 South America 47

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.3 Europe 50

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.3.1 Western Europe 52

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.3.1.1 Germany 54

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.3.1.2 U.K 56

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.3.1.3 France 57

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.3.1.4 Spain 59

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.3.1.5 Italy 61

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.3.1.6 Rest Of Western Europe 62

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.3.2 Eastern Europe 64

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.4 Asia Pacific 66

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.4.1 China 68

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.4.2 Japan 70

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.4.3 India 71

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.4.4 Australia 73

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.4.5 Republic Of Korea 75

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.4.6 Rest Of Asia Pacific 76

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.5 Middle East & Africa 79

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.5.1 Middle East 81

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.5.2 Africa 83

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

10 Competitive Landscape

10.1 Introduction 86

11 Company Profiles

11.1 Greiner Bio-One International GmbH 88

11.1.1 Company Overview 88

11.1.2 Financial Overview 88

11.1.3 Products Offering 89

11.1.4 Key Developments 89

11.1.5 SWOT Analysis 89

11.1.6 Key Strategy 89

11.2 Ikonisys Inc. 90

11.2.1 Company Overview 90

11.2.2 Financial Overview 90

11.2.3 Products Offering 90

11.2.4 Key Developments 90

11.2.5 SWOT Analysis 90

11.2.6 Key Strategy 90

11.3 Thermo Fisher Scientific 91

11.3.1 Company Overview 91

11.3.2 Financial Overview 91

11.3.3 Products Offering 92

11.3.4 Key Developments 92

11.3.5 SWOT Analysis 92

11.3.6 Key Strategy 92

11.4 SRI International 93

11.4.1 Company Overview 93

11.4.2 Financial Overview 93

11.4.3 Products Offering 93

11.4.4 Key Developments 93

11.4.5 SWOT Analysis 94

11.4.6 Key Strategy 94

11.5 STEMCELL Technologies 95

11.5.1 Company Overview 95

11.5.2 Financial Overview 95

11.5.3 Products Offering 95

11.5.4 Key Developments 95

11.5.5 SWOT Analysis 95

11.5.6 Key Strategy 95

11.6 Miltenyi Biotec 96

11.6.1 Company Overview 96

11.6.2 Financial Overview 96

11.6.3 Products Offering 96

11.6.4 Key Developments 96

11.6.5 SWOT Analysis 96

11.6.6 Key Strategy 97

11.7 Menarini Silicon Biosystems 98

11.7.1 Company Overview 98

11.7.2 Financial Overview 98

11.7.3 Products Offering 98

11.7.4 Key Developments 98

11.7.5 SWOT Analysis 98

11.7.6 Key Strategy 98

11.8 QIAGEN Hannover (QIAGEN) 99

11.8.1 Company Overview 99

11.8.2 Financial Overview 99

11.8.3 Products Offering 99

11.8.4 Key Developments 100

11.8.5 SWOT Analysis 100

11.8.6 Key Strategy 100

11.9 F. Hoffmann-La Roche Ltd 101

11.9.1 Company Overview 101

11.9.2 Financial Overview 101

11.9.3 Products Offering 102

11.9.4 Key Developments 102

11.9.5 SWOT Analysis 102

11.9.6 Key Strategy 102

11.10 NanoString Technologies, Inc. 103

11.10.1 Company Overview 103

11.10.2 Financial Overview 103

11.10.3 Products Offering 103

11.10.4 Key Developments 104

11.10.5 SWOT Analysis 104

11.10.6 Key Strategy 104

11.11 Fluxion Biosciences, Inc. 105

11.11.1 Company Overview 105

11.11.2 Financial Overview 105

11.11.3 Products Offering 105

11.11.4 Key Developments 105

11.11.5 SWOT Analysis 105

11.11.6 Key Strategy 106

11.12 GE Healthcare 107

11.12.1 Company Overview 107

11.12.2 Financial Overview 107

11.12.3 Products Offering 107

11.12.4 Key Developments 108

11.12.5 SWOT Analysis 108

11.12.6 Key Strategy 108

12 Appendix

12.1 Discussion Blue Print 110

13 List Of Tables

TABLE 1 GLOBAL CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 29

TABLE 2 GLOBAL CIRCULATING TUMOR CELL MARKET FOR CLINICAL APPLICATION 2023-2030 (USD MILLION) 30

TABLE 3 GLOBAL CIRCULATING TUMOR CELL MARKET FOR RESEARCH APPLICATION 2023-2030 (USD MILLION) 30

TABLE 4 GLOBAL CIRCULATING TUMOR CELL MARKET FOR DRUG DEVELOPMENT APPLICATION 2023-2030 (USD MILLION) 31

TABLE 5 GLOBAL CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 33

TABLE 6 GLOBAL CIRCULATING TUMOR CELL MARKET FOR CTC ENRICHMENT 2023-2030 (USD MILLION) 34

TABLE 7 GLOBAL CIRCULATING TUMOR CELL MARKET FOR CTC DETECTION 2023-2030 (USD MILLION) 34

TABLE 8 GLOBAL CIRCULATING TUMOR CELL MARKET FOR COMBINED ENRICHMENT AND SEPARATION OF CTC (CTC ANALYSIS) 2023-2030

(USD MILLION) 34

TABLE 9 GLOBAL CIRCULATING TUMOR CELL MARKET, BY END-USER 2023-2030 (USD MILLION) 36

TABLE 10 GLOBAL CIRCULATING TUMOR CELL MARKET FOR HOSPITAL & CLINICS 2023-2030 (USD MILLION) 37

TABLE 11 GLOBAL CIRCULATING TUMOR CELL MARKET FOR RESEARCH & ACADEMIC INSTITUTES 2023-2030 (USD MILLION) 37

TABLE 12 GLOBAL CIRCULATING TUMOR CELL MARKET FOR DIAGNOSTIC CENTERS 2023-2030 (USD MILLION) 37

TABLE 13 GLOBAL CIRCULATING TUMOR CELL MARKET, BY REGION 2023-2030 (USD MILLION) 39

TABLE 14 AMERICAS CIRCULATING TUMOR CELL MARKET, BY REGION 2023-2030 (USD MILLION) 40

TABLE 15 AMERICAS CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 41

TABLE 16 AMERICAS CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 41

TABLE 17 AMERICAS CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 41

TABLE 18 AMERICAS CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 42

TABLE 19 AMERICAS CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 42

TABLE 20 NORTH AMERICA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 42

TABLE 21 NORTH AMERICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 43

TABLE 22 NORTH AMERICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 43

TABLE 23 NORTH AMERICA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 43

TABLE 24 NORTH AMERICA CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 44

TABLE 25 U.S CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 44

TABLE 26 U.S CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 44

TABLE 27 U.S CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 45

TABLE 28 U.S CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 45

TABLE 29 U.S CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 45

TABLE 30 CANADA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 46

TABLE 31 CANADA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 46

TABLE 32 CANADA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 46

TABLE 33 CANADA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 47

TABLE 34 CANADA CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 47

TABLE 35 SOUTH AMERICA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 47

TABLE 36 SOUTH AMERICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 48

TABLE 37 SOUTH AMERICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 48

TABLE 38 SOUTH AMERICA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 48

TABLE 39 SOUTH AMERICA CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 49

TABLE 40 EUROPE CIRCULATING TUMOR CELL MARKET, BY REGION 2023-2030 (USD MILLION) 50

TABLE 41 EUROPE CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 51

TABLE 42 EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 51

TABLE 43 EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 51

TABLE 44 EUROPE CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 52

TABLE 45 EUROPE CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 52

TABLE 46 WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 52

TABLE 47 WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 53

TABLE 48 WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 53

TABLE 49 WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 53

TABLE 50 WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 54

TABLE 51 GERMANY CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 54

TABLE 52 GERMANY CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 54

TABLE 53 GERMANY CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 55

TABLE 54 GERMANY CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 55

TABLE 55 GERMANY CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 55

TABLE 56 U.K CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 56

TABLE 57 U.K CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 56

TABLE 58 U.K CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 56

TABLE 59 U.K CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 57

TABLE 60 U.K CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 57

TABLE 61 FRANCE CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 57

TABLE 62 FRANCE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 58

TABLE 63 FRANCE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 58

TABLE 64 FRANCE CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 58

TABLE 65 FRANCE CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 59

TABLE 66 SPAIN CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 59

TABLE 67 SPAIN CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 59

TABLE 68 SPAIN CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 60

TABLE 69 SPAIN CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 60

TABLE 70 SPAIN CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 60

TABLE 71 ITALY CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 61

TABLE 72 ITALY CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 61

TABLE 73 ITALY CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 61

TABLE 74 ITALY CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 62

TABLE 75 ITALY CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 62

TABLE 76 REST OF WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 62

TABLE 77 REST OF WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 63

TABLE 78 REST OF WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 63

TABLE 79 REST OF WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 63

TABLE 80 REST OF WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 64

TABLE 81 EASTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 64

TABLE 82 EASTERN EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 64

TABLE 83 EASTERN EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 65

TABLE 84 EASTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 65

TABLE 85 EASTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 65

TABLE 86 ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, BY COUNTRY 2023-2030 (USD MILLION) 66

TABLE 87 ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 66

TABLE 88 ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 67

TABLE 89 ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 67

TABLE 90 ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 67

TABLE 91 ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 68

TABLE 92 CHINA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 68

TABLE 93 CHINA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 68

TABLE 94 CHINA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 69

TABLE 95 CHINA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 69

TABLE 96 CHINA CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 69

TABLE 97 JAPAN CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 70

TABLE 98 JAPAN CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 70

TABLE 99 JAPAN CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 70

TABLE 100 JAPAN CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 71

TABLE 101 JAPAN CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 71

TABLE 102 INDIA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 71

TABLE 103 INDIA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 72

TABLE 104 INDIA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 72

TABLE 105 INDIA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 72

TABLE 106 INDIA CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 73

TABLE 107 AUSTRALIA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 73

TABLE 108 AUSTRALIA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 73

TABLE 109 AUSTRALIA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 74

TABLE 110 AUSTRALIA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 74

TABLE 111 AUSTRALIA CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 74

TABLE 112 REPUBLIC OF KOREA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 75

TABLE 113 REPUBLIC OF KOREA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 75

TABLE 114 REPUBLIC OF KOREA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 75

TABLE 115 REPUBLIC OF KOREA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 76

TABLE 116 REPUBLIC OF KOREA CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 76

TABLE 117 REST OF ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 76

TABLE 118 REST OF ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 77

TABLE 119 REST OF ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 77

TABLE 120 REST OF ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 77

TABLE 121 REST OF ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 78

TABLE 122 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET, BY REGION 2023-2030 (USD MILLION) 79

TABLE 123 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 79

TABLE 124 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 80

TABLE 125 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 80

TABLE 126 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 80

TABLE 127 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 81

TABLE 128 MIDDLE EAST CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 81

TABLE 129 MIDDLE EAST CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 81

TABLE 130 MIDDLE EAST CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 82

TABLE 131 MIDDLE EAST CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 82

TABLE 132 MIDDLE EAST CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 82

TABLE 133 AFRICA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023-2030 (USD MILLION) 83

TABLE 134 AFRICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2023-2030 (USD MILLION) 83

TABLE 135 AFRICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2023-2030 (USD MILLION) 83

TABLE 136 AFRICA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION) 84

TABLE 137 AFRICA CIRCULATING TUMOR CELL MARKET, BY END USER 2023-2030 (USD MILLION) 84

TABLE 138 TOP MANUFACTURERS IN THE GLOBAL CIRCULATING TUMOR CELLS MARKET 2023 86

14 List Of Figures

FIGURE 1 MARKET STRUCTURE 17

FIGURE 2 RESEARCH PROCESS 19

FIGURE 3 DRO ANALYSIS OF GLOBAL CIRCULATING TUMOR CELL MARKET 22

FIGURE 4 VALUE CHAIN: GLOBAL CIRCULATING TUMOR CELL MARKET 25

FIGURE 5 PORTER’S FIVE FORCES MODEL: GLOBAL CIRCULATING TUMOR CELL MARKET 26

FIGURE 6 GLOBAL CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2023 & 2030 (USD MILLION) 30

FIGURE 7 GLOBAL CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2023 & 2030 (USD MILLION) 33

FIGURE 8 GLOBAL CIRCULATING TUMOR CELL MARKET, BY END-USER 2023 & 2030 (USD MILLION) 36

FIGURE 9 GLOBAL CIRCULATING TUMOR CELL MARKET SHARE, BY REGION 2023 (%) 40

FIGURE 10 AMERICAS CIRCULATING TUMOR CELL MARKET SHARE, BY REGION 2023 (%) 40

FIGURE 11 EUROPE CIRCULATING TUMOR CELL MARKET SHARE, BY REGION 2023 (%) 50

FIGURE 12 ASIA PACIFIC CIRCULATING TUMOR CELL MARKET SHARE, BY REGION 2023 (%) 66

FIGURE 13 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SHARE, BY REGION 2023 (%) 79

Circulating Tumor Cell Market Segmentation


Circulating Tumor Cell Type Outlook (USD Billion, 2019-2030)




  • Research




  • Drug Development




Circulating Tumor Cell Technology Outlook (USD Billion, 2019-2030)




  • CTC Enrichment




  • CTC Detection




Circulating Tumor Cell End User Outlook (USD Billion, 2019-2030)




  • Hospital & Clinics




  • Research & Academic Institutes




  • Diagnostic Centers




Circulating Tumor Cell Regional Outlook (USD Billion, 2019-2030)




  • North America Outlook (USD Billion, 2019-2030)




    • North America Circulating Tumor Cell by Technology




      • Research




      • Drug Development






    • North America Circulating Tumor Cell by Technology




      • CTC Enrichment




      • CTC Detection






    • North America Circulating Tumor Cell by End User




      • Hospital & Clinics




      • Research & Academic Institutes




      • Diagnostic Centers






    • US Outlook (USD Billion, 2019-2030)




    • US Circulating Tumor Cell by Technology




      • Research




      • Drug Development






    • US Circulating Tumor Cell by Technology




      • CTC Enrichment




      • CTC Detection






    • US Circulating Tumor Cell by End User




      • Hospital & Clinics




      • Research & Academic Institutes




      • Diagnostic Centers






    • CANADA Outlook (USD Billion, 2019-2030)




    • CANADA Circulating Tumor Cell by Technology




      • Research




      • Drug Development






    • CANADA Circulating Tumor Cell by Technology




      • CTC Enrichment




      • CTC Detection






    • CANADA Circulating Tumor Cell by End User




      • Hospital & Clinics




      • Research & Academic Institutes




      • Diagnostic Centers








  • Europe Outlook (USD Billion, 2019-2030)




    • Europe Circulating Tumor Cell by Technology




      • Research




      • Drug Development






    • Europe Circulating Tumor Cell by Technology




      • CTC Enrichment




      • CTC Detection






    • Europe Circulating Tumor Cell by End User




      • Hospital & Clinics




      • Research & Academic Institutes




      • Diagnostic Centers






    • Germany Outlook (USD Billion, 2019-2030)




    • Germany Circulating Tumor Cell by Technology




      • Research




      • Drug Development






    • Germany Circulating Tumor Cell by Technology




      • CTC Enrichment




      • CTC Detection






    • Germany Circulating Tumor Cell by End User




      • Hospital & Clinics




      • Research & Academic Institutes




      • Diagnostic Centers






    • France Outlook (USD Billion, 2019-2030)




    • France Circulating Tumor Cell by Technology




      • Research




      • Drug Development






    • France Circulating Tumor Cell by Technology




      • CTC Enrichment




      • CTC Detection






    • France Circulating Tumor Cell by End User




      • Hospital & Clinics




      • Research & Academic Institutes




      • Diagnostic Centers






    • UK Outlook (USD Billion, 2019-2030)




    • UK Circulating Tumor Cell by Technology




      • Research




      • Drug Development






    • UK Circulating Tumor Cell by Technology




      • CTC Enrichment




      • CTC Detection






    • UK Circulating Tumor Cell by End User




      • Hospital & Clinics




      • Research & Academic Institutes




      • Diagnostic Centers






    • ITALY Outlook (USD Billion, 2019-2030)




    • ITALY Circulating Tumor Cell by Technology




      • Research




      • Drug Development






    • ITALY Circulating Tumor Cell by Technology




      • CTC Enrichment




      • CTC Detection






    • ITALY Circulating Tumor Cell by End User




      • Hospital & Clinics




      • Research & Academic Institutes




      • Diagnostic Centers






    • SPAIN Outlook (USD Billion, 2019-2030)




    • Spain Circulating Tumor Cell by Technology




      • Research




      • Drug Development






    • Spain Circulating Tumor Cell by Technology




      • CTC Enrichment




      • CTC Detection






    • Spain Circulating Tumor Cell by End User




      • Hospital & Clinics




      • Research & Academic Institutes




      • Diagnostic Centers






    • Rest Of Europe Outlook (USD Billion, 2019-2030)




    • Rest Of Europe Circulating Tumor Cell by Technology




      • Research




      • Drug Development






    • REST OF EUROPE Circulating Tumor Cell by Technology




      • CTC Enrichment




      • CTC Detection






    • REST OF EUROPE Circulating Tumor Cell by End User




      • Hospital & Clinics




      • Research & Academic Institutes




      • Diagnostic Centers








  • Asia-Pacific Outlook (USD Billion, 2019-2030)




    • Asia-Pacific Circulating Tumor Cell by Technology




      • Research




      • Drug Development






    • Asia-Pacific Circulating Tumor Cell by Technology




      • CTC Enrichment




      • CTC Detection






    • Asia-Pacific Circulating Tumor Cell by End User




      • Hospital & Clinics




      • Research & Academic Institutes




      • Diagnostic Centers






    • China Outlook (USD Billion, 2019-2030)




    • China Circulating Tumor Cell by Technology




      • Research




      • Drug Development






    • China Circulating Tumor Cell by Technology




      • CTC Enrichment




      • CTC Detection






    • China Circulating Tumor Cell by End User




      • Hospital & Clinics




      • Research & Academic Institutes




      • Diagnostic Centers






    • Japan Outlook (USD Billion, 2019-2030)




    • Japan Circulating Tumor Cell by Technology




      • Research




      • Drug Development






    • Japan Circulating Tumor Cell by Technology




      • CTC Enrichment




      • CTC Detection






    • Japan Circulating Tumor Cell by End User




      • Hospital & Clinics




      • Research & Academic Institutes




      • Diagnostic Centers






    • India Outlook (USD Billion, 2019-2030)




    • India Circulating Tumor Cell by Technology




      • Research




      • Drug Development






    • India Circulating Tumor Cell by Technology




      • CTC Enrichment




      • CTC Detection






    • India Circulating Tumor Cell by End User




      • Hospital & Clinics




      • Research & Academic Institutes




      • Diagnostic Centers






    • Australia Outlook (USD Billion, 2019-2030)




    • Australia Circulating Tumor Cell by Technology




      • Research




      • Drug Development






    • Australia Circulating Tumor Cell by Technology




      • CTC Enrichment




      • CTC Detection






    • Australia Circulating Tumor Cell by End User




      • Hospital & Clinics




      • Research & Academic Institutes




      • Diagnostic Centers






    • Rest of Asia-Pacific Outlook (USD Billion, 2019-2030)




    • Rest of Asia-Pacific Circulating Tumor Cell by Technology




      • Research




      • Drug Development






    • Rest of Asia-Pacific Circulating Tumor Cell by Technology




      • CTC Enrichment




      • CTC Detection






    • Rest of Asia-Pacific Circulating Tumor Cell by End User




      • Hospital & Clinics




      • Research & Academic Institutes




      • Diagnostic Centers








  • Rest of the World Outlook (USD Billion, 2019-2030)




    • Rest of the World Circulating Tumor Cell by Technology




      • Research




      • Drug Development






    • Rest of the World Circulating Tumor Cell by Technology




      • CTC Enrichment




      • CTC Detection






    • Rest of the World Circulating Tumor Cell by End User




      • Hospital & Clinics




      • Research & Academic Institutes




      • Diagnostic Centers






    • Middle East Outlook (USD Billion, 2019-2030)




    • Middle East Circulating Tumor Cell by Technology




      • Research




      • Drug Development






    • Middle East Circulating Tumor Cell by Technology




      • CTC Enrichment




      • CTC Detection






    • Middle East Circulating Tumor Cell by End User




      • Hospital & Clinics




      • Research & Academic Institutes




      • Diagnostic Centers




      •  






    • Africa Outlook (USD Billion, 2019-2030)




    • Africa Circulating Tumor Cell by Technology




      • Research




      • Drug Development






    • Africa Circulating Tumor Cell by Technology




      • CTC Enrichment




      • CTC Detection






    • Africa Circulating Tumor Cell by End User




      • Hospital & Clinics




      • Research & Academic Institutes




      • Diagnostic Centers






    • Latin America Outlook (USD Billion, 2019-2030)




    • Latin America Circulating Tumor Cell by Technology




      • Research




      • Drug Development






    • Latin America Circulating Tumor Cell by Technology




      • CTC Enrichment




      • CTC Detection






    • Latin America Circulating Tumor Cell by End User




      • Hospital & Clinics




      • Research & Academic Institutes




      • Diagnostic Centers







Leading companies partner with us for data-driven Insights.
Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid